De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

argenx Toekomstige groei

Future criteriumcontroles 6/6

argenx zal naar verwachting groeien in winst en omzet met respectievelijk 58.5% en 26.4% per jaar. De winst per aandeel zal naar verwachting groeien met 58.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 20.7% zijn.

Belangrijke informatie

58.8%

Groei van de winst

58.5%

Groei van de winst per aandeel

Biotechs winstgroei	34.8%
Inkomstengroei	26.3%
Toekomstig rendement op eigen vermogen	20.7%
Dekking van analisten	Good
Laatst bijgewerkt	03 Oct 2024

Recente toekomstige groei-updates

Results: argenx SE Confounded Analyst Expectations With A Surprise Profit

Jul 29

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Mar 24

Recent updates

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Mar 24

Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report

Mar 05

argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate

Feb 23

Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely

Dec 18

Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher

Jul 28

An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued

Jul 17

Revenues Tell The Story For argenx SE (EBR:ARGX)

Jun 20

argenx (EBR:ARGX) Is Using Debt Safely

May 08

We Think argenx (EBR:ARGX) Can Afford To Drive Business Growth

Apr 20

Does argenx (EBR:ARGX) Have A Healthy Balance Sheet?

Dec 27

Winst- en omzetgroeiprognoses

ENXTBR:ARGX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	3,654	1,041	863	866	22
12/31/2025	2,824	415	155	223	27
12/31/2024	2,020	-8	-378	-393	27
6/30/2024	1,660	-204	-325	-260	N/A
3/31/2024	1,451	-328	N/A	N/A	N/A
12/31/2023	1,269	-295	-464	-420	N/A
9/30/2023	1,029	-234	N/A	N/A	N/A
6/30/2023	835	-397	-758	-654	N/A
3/31/2023	639	-511	N/A	N/A	N/A
12/31/2022	441	-710	-967	-863	N/A
9/30/2022	286	-909	N/A	N/A	N/A
6/30/2022	146	-907	-874	-876	N/A
3/31/2022	381	-595	N/A	N/A	N/A
12/31/2021	528	-408	-728	-607	N/A
9/30/2021	510	-373	N/A	N/A	N/A
6/30/2021	526	-319	-601	-474	N/A
3/31/2021	206	-573	N/A	N/A	N/A
12/31/2020	62	-608	-404	-398	N/A
9/30/2020	75	-535	N/A	N/A	N/A
6/30/2020	70	-359	-263	-255	N/A
3/31/2020	73	-275	N/A	N/A	N/A
12/31/2019	93	-181	105	152	N/A
9/30/2019	72	-109	N/A	N/A	N/A
6/30/2019	68	-104	188	230	N/A
3/31/2019	70	-47	N/A	N/A	N/A
12/31/2018	33	-76	-62	-62	N/A
9/30/2018	41	-56	N/A	N/A	N/A
6/30/2018	44	-47	-57	-57	N/A
3/31/2018	50	-46	N/A	N/A	N/A
12/31/2017	49	-34	N/A	-44	N/A
9/30/2017	42	-30	N/A	N/A	N/A
6/30/2017	39	-25	N/A	-31	N/A
3/31/2017	23	-29	N/A	N/A	N/A
12/31/2016	18	-22	N/A	11	N/A
9/30/2016	17	-20	N/A	N/A	N/A
6/30/2016	14	-17	N/A	16	N/A
3/31/2016	12	-17	N/A	N/A	N/A
12/31/2015	11	-17	N/A	-15	N/A
9/30/2015	10	-16	N/A	N/A	N/A
6/30/2015	9	-14	N/A	-10	N/A
3/31/2015	7	-12	N/A	N/A	N/A
12/31/2014	7	-12	N/A	-6	N/A
9/30/2014	6	-10	N/A	N/A	N/A
6/30/2014	7	-8	N/A	-6	N/A
3/31/2014	7	-9	N/A	-8	N/A
12/31/2013	7	-8	N/A	-9	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat ARGX de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 1.3% ).

Winst versus markt: Er wordt verwacht dat ARGX de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat ARGX binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van ARGX ( 26.4% per jaar) zal naar verwachting sneller groeien dan de markt Belgian ( 7.5% per jaar).

Hoge groei-inkomsten: De omzet van ARGX ( 26.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ARGX zal naar verwachting over 3 jaar hoog zijn ( 20.7 %)

argenx Toekomstige groei

Future criteriumcontroles 6/6

Belangrijke informatie

Recente toekomstige groei-updates

Results: argenx SE Confounded Analyst Expectations With A Surprise Profit

Forecast to breakeven in 2025

Consensus EPS estimates fall by 12%, revenue upgraded

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Consensus EPS estimates upgraded to US$1.43 loss

Consensus estimates of losses per share improve by 13%

Recent updates

Argenx Announces Publication in the Lancet Neurology of Pivotal Adhere Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Is argenx SE (EBR:ARGX) Trading At A 45% Discount?

Independent Non-Executive Director recently sold €1.9m worth of stock

Results: argenx SE Confounded Analyst Expectations With A Surprise Profit

Forecast to breakeven in 2025

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

argenx SE to Report Fiscal Year 2024 Results on Feb 27, 2025

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

argenx SE's (EBR:ARGX) Shares Climb 26% But Its Business Is Yet to Catch Up

argenx SE Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2024 earnings released: US$1.04 loss per share (vs US$0.52 loss in 1Q 2023)

argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors

argenx SE's (EBR:ARGX) CEO Looks Like They Deserve Their Pay Packet

argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Investors Appear Satisfied With argenx SE's (EBR:ARGX) Prospects

argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Consensus EPS estimates upgraded to US$1.43 loss

Consensus estimates of losses per share improve by 13%

Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE, Annual General Meeting, May 07, 2024

CEO & Executive Director recently sold €1.0m worth of stock

Price target decreased by 11% to €459

argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Consensus EPS estimates upgraded to US$4.76 loss, revenue downgraded

argenx SE Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

Consensus EPS estimates fall by 17%

argenx SE Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

Argenx Se Announces 20 Presentations of Clinical Trial and Real-World Data from Studies of Vyvgart® and Vyvgart Hytrulo® (Vyvgart) in Neuromuscular Autoimmune Disease

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 16%

Consensus EPS estimates fall by 19%

Independent Chairman of the Board recently sold €3.8m worth of stock

Argenx Announces VYVGART (Efgartigimod Alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

CEO & Executive Director exercised options to buy €36m worth of stock.

CEO & Executive Director recently sold €1.9m worth of stock

Independent Non-Executive Director exercised options and sold €3.3m worth of stock

Consensus EPS estimates upgraded to US$4.71 loss

Consensus revenue estimates increase by 10%

Price target increased by 8.0% to €491

Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

New minor risk - Shareholder dilution

Price target increased by 9.4% to €476

New major risk - Share price stability

Consensus EPS estimates upgraded to US$5.73 loss

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Forecast to breakeven in 2025

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis

Revenues Tell The Story For argenx SE (EBR:ARGX)

Now 20% undervalued

Consensus EPS estimates upgraded to US$6.53 loss

Now 21% undervalued

Consensus estimates of losses per share improve by 13%

argenx (EBR:ARGX) Is Using Debt Safely

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025